Two or three out of every 100 infants under 6 months old are hospitalized with RSV annually, according to federal estimates. Shannon Stapleton/Reuters

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following concerns raised by vaccine skeptics, multiple sources familiar with the situation told Reuters.

The preventive therapies - Beyfortus from Sanofi (SASY.PA), opens new tab and AstraZeneca (AZN.L), opens new tab and Enflonsia from Merck (MRK.N), opens new tab - would be the latest called into question under U.S. Health Secretary Robert F. Kennedy Jr., a long-time promoter of anti-vaccine views who is presiding over a review of routine childhood

See Full Page